Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria

Chronic urticaria (CU) is a debilitating skin disease affecting around 1% of the population. CU can be subdivided into chronic spontaneous (CSU) and inducible (CIndU). Different pathophysiological mechanisms have been proposed to play role in development CU, these are also being investigated as potential biomarkers diagnosis management disease. As now only assessment tools available for treatment response patient reported outcomes (PROs). Although both validated widely used, they leave desire more objective measurements. A biomarker broad subcategory observations that used an accurate, reproducible, indicator clinically relevant outcomes. This could normal biological or pathogenic processes, intervention exposure, e.g., response. Herein we provide overview with focus on prognostic omalizumab, thereby potentially aiding physicians personalizing treatments.